GLI AGENTI CHE SEQUESTRANO GLI ACIDI BILIARI MIGLIORANO NETTAMENTE GLI ESITI CLINICI DELLA COLITE MICROSCOPICA ! UNO STUDIO DI COORTE SU 282 PAZIENTI DALLA MAYO. DA “Clinical Gastroenterology and Hepatology”

DISORDINI FUNZIONALI, GASTROENTEROLOGIA, IBD, NEWSLETTER, Senza categoria

Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing June Tome et al. Abstract BACKGROUND Bile acid sequestrants (BAS) may be a treatment in microscopic colitis (MC), but efficacy data are limited. We evaluated the effectiveness of BAS in MC and assessed the utility of bile acid testing to predict response.…

ATTENZIONE: UNO STUDIO DI REAL-WORLD ANALYSIS DALLA GERMANIA SUGGERISCE UN AUMENTO DELLA DEMENZA IN CHI USA CONTINUATIVAMENTE PPI. DA “DRUGS AGING”

GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, REAL WORLD EVIDENCE, Senza categoria

Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany Nayeon Ahn et al. Abstract Background: Cumulative evidence of dementia risk in patients taking proton pump inhibitors (PPIs) is still inconclusive, probably due to a variety of study designs. Objective: This study aimed to compare how the association between dementia risk…

DIAGNOSI E GESTIONE CLINICA DELLA CIRROSI. UN OTTIMO APPROCCIO EBM. DA “JAMA”

CIRROSI EPATICA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, Senza categoria

Diagnosis and Management of Cirrhosis and Its Complications. A Review Elliot B. Tapper, Neehar D. Parikh, Abstract Importance  Cirrhosis affects approximately 2.2 million adults in the US. From 2010 to 2021, the annual age-adjusted mortality of cirrhosis increased from 14.9 per 100 000 to 21.9 per 100 000 people. Observations  The most common causes of cirrhosis in the US, which…

RISCHIO DI MORTALITA’ PER LA NASH A SECONDA DEL GRADO DI FIBROSI. UNA GRANDE META-ANALISI DA “CLINICAL GASTROENTEROLOGY & HEPATOLOGY” (FREE)

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoria

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis Cheng Han Ng et al. Background & Aims Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty liver disease (NAFLD), but time-dependent risk of mortality has not been reported in previous meta-analyses. We performed an updated time-to-event meta-analysis…

RIFAXIMINA PER LA MALATTIA EPATICA DA ALCOL. UN EDITORIALE DA “LANCET” (FREE).

EPATOLOGIA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Rifaximin-α in alcohol-associated liver disease Chencheng Xie et al Alcohol-associated liver disease is the most common cause of cirrhosis and a leading indication for liver transplantation in the USA and worldwide. A public health concern, the morbidity and mortality of alcohol-associated liver disease has accelerated globally since the COVID-19 pandemic due to rising alcohol consumption.…

LA RIFAXIMINA RIDUCE LA PROGRESSIONE DELLA FIBROSI NELLA MALATTIA EPATICA DA ALCOL ! 1100 MG AL GIORNO PER 18 MESI: RIDUZIONE DEL 20% DI PROGRESSIONE VS PLACEBO odds ratio 0,42 [0·18–0·98]; p=0·044. RCT SU BIOPSIE DA “LANCET” (FREE)

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial Mads Israelsen et al. Summary Background Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients…